BioSight
Companies
Immix Biopharma, Inc. logo

IMMX

NASDAQLOS ANGELES, CA
Immix Biopharma, Inc.

Immix Biopharma is a clinical-stage biopharmaceutical company focused on CAR-T cell therapy for light chain amyloidosis and other serious diseases, with its lead candidate NXC-201 currently in Phase 1b/2 trials in the United States (NEXICART-2) and ex-U.S. (NEXICART-1). NXC-201 has received FDA Breakthrough Therapy designation, RMAT designation, and Orphan Drug designation for relapsed/refractory AL amyloidosis, with December 2025 interim data showing 75 percent complete response rates and favorable safety profiles in evaluable patients. The company plans to submit a Biologics License Application following completion of the NEXICART-2 trial, which is expected to enroll 40 patients total.

Price history not yet available for IMMX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar